ProCE Banner Activity

Moving Toward Greater Options for HIV PrEP

Conference Coverage
Clinical Thought
Since the introduction of daily oral FTC/TDF PrEP 8 years ago, new options have emerged and promising new data on investigational strategies that do not require daily oral dosing suggest that highly effective HIV prevention modalities will continue to expand. Here’s my take on new PrEP data from AIDS 2020: Virtual.

Released: August 19, 2020

Expiration: August 18, 2021

No longer available for credit.

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.